Join us.

We’re working to create a just society and preserve a healthy environment for future generations. Donate today to help.

Donate

Blog

Showing 269 results

James Goodwin

Policy Director

James Goodwin | July 1, 2009

Pentagon Continues to Press Its Case for Behind-the-Scenes Interference at OMB

Earlier this month, representatives from the military and a number of defense contractors had a closed-door meeting with officials at OMB's Office of Information and Regulatory Affairs (OIRA).  The topic under discussion was ostensibly a Safe Drinking Water Act regulation for perchlorate—a highly toxic chemical used in the manufacture of rocket fuel—that the EPA is currently […]

James Goodwin | June 8, 2009

The Trials and Tribulations of Obama’s Open Government Initiative

When President Obama launched his open government initiative on his first full day on the job, few assumed that the ambitious endeavor it contemplated would be easy.  After all, lack of transparency and even active efforts to conceal information had become almost an inextricable feature of the federal government’s internal operations and decision-making—especially during the […]

James Goodwin | June 4, 2009

FDA’s Transparency Initiative: New Life in a Glass House?

In 2007, the FDA came under criticism for failing to inform the public about studies it had had for two years which indicated that users of the diabetes drug Avandia faced up to a 42% greater chance of suffering a heart attack.  More recently, it was revealed that Bush-era political appointees at the agency surreptitiously worked […]

James Goodwin | May 4, 2009

Judicial Review and Cost-Benefit Analysis: Part II

Last week I discussed how the institution of judicial review has been used to amplify the deregulatory nature of cost-benefit analysis.  This week, I'll talk about some possible remedies. An unusual synergy exists between the institutions of cost-benefit analysis and judicial review.  Under most circumstances, the institution of judicial review is arguably neutral with regard to […]

James Goodwin | May 1, 2009

Judicial Review and Cost-Benefit Analysis

For the last few years now, CPR’s Member Scholars have made the case that cost-benefit analysis is, by itself, fundamentally deregulatory in nature.  Unfortunately, other institutions in our federal government tend to exacerbate the deregulatory nature of cost-benefit analysis.  Whether by design or dumb luck, cost-benefit analysis allows regulatory opponents to use those institutions—most notably […]

James Goodwin | April 8, 2009

Climate Change: Endangering Our Future, Destroying Our Past

The large earthquake that struck central Italy on Monday is devastating not only for the immense human suffering—people killed and injured, and communities disrupted—but also for the priceless losses of Italian cultural heritage.  The Italian Ministry of culture has reported that the earthquake damaged a number of buildings of immeasurable historical significance, including the Basilica di […]

James Goodwin | March 26, 2009

What Others Are Saying About the Future of Regulatory Review

More than 100 groups and individuals have accepted the invitation from the Office of Management and Budget (OMB) to comment on the new Executive Order on Regulatory Review that the Obama Administration is currently considering.  The extended submission deadline is March 31.  So far, the comments reflect a strikingly wide dividing line between regulatory opponents, […]

James Goodwin | February 26, 2009

Another Twist in the Mercury Air Pollution Saga

On Monday, the U.S. Supreme Court announced that it would not be accepting an appeal of a case involving the Bush Administration’s regulatory plan for reducing air mercury emissions from power plants.  For the last two decades, the regulation of mercury air pollution has been caught up in a long and winding journey reminiscent of Homer’s […]

James Goodwin | February 20, 2009

The Backdoor Discrimination of Cost-Benefit Analysis

In recent weeks, an unusual convergence of events has served to elevate somewhat the public profile of cost-benefit analysis (CBA).  Before then, CBA was an obscure and highly complex tool of policy analysis—the kind of thing that hardcore policy wonks would wonk about when the subjects of their usual policy wonkery weren’t wonkish enough.  Foreseeable […]